01 Chromogenic Factor VIII Testing for Hemophilia A Monitoring The bleeding disorder testing market analysis shows that specialized testing is needed to monitor factor VIII activity in patients receiving emicizumab therapy. This encourages laboratories to use chromogenic assays with bovine reagents to avoid drug interference and improve test accuracy. For example, the World Federation of Hemophilia recommends bovine-reagent chromogenic assays for factor VIII measurement during emicizumab treatment.
02 Sequential Testing for von Willebrand Disease Diagnosis Laboratories are using combined tests for von Willebrand factor (VWF) antigen, VWF activity, and factor VIII levels to support von Willebrand disease diagnosis. This approach helps distinguish disease subtypes and determine the need for further testing. The ASH/ISTH/NHF/WFH guidelines recommend specific VWF activity assays as part of the diagnostic process.
01 The bleeding disorder testing market forecasts strategic investment activity driven by the development of rapid coagulation diagnostic platforms, point-of-care testing technologies, hemophilia monitoring assays, and advanced hemostasis testing systems.
02 Key Investment and Funding Activities in Bleeding Disorder Testing Market, 2026 Company Value (USD) Details Abram Scientific Up to USD 8.3 million In October 2026, Abram Scientific announced a DARPA contract worth up to USD 8.3 million to advance its handheld CoagCare blood-coagulation testing platform for trauma care. Abram Scientific USD 11.75 million In February 2026, Abram Scientific closed a Series A financing round led by Octapharma AG, with participation from new and existing investors affiliated with the University of Colorado Anschutz.
01 Confirmatory Testing Demand for Acquired Hemophilia A Drives Market Acquired hemophilia A causes spontaneous bleeding in individuals without a previous history of bleeding disorders, making accurate laboratory confirmation essential. Factor VIII activity assays and inhibitor tests help distinguish acquired hemophilia A from other causes of abnormal coagulation results. This supports demand for specialized diagnostic testing to confirm factor VIII inhibitors and guide appropriate clinical management.
02 Diagnosis of Rare Coagulation Factor Deficiencies Drives Bleeding Disorder Testing Market Demand Rare deficiencies involving coagulation factors such as V, VII, X, XI, and XIII produce similar bleeding symptoms but require different diagnostic tests. Routine coagulation results do not identify the specific deficiency, particularly in cases such as factor XIII deficiency, where prothrombin time and activated partial thromboplastin time remain normal. This drives demand for factor-specific activity assays that help establish an accurate diagnosis and support treatment decisions.
03 Impact Analysis of Key Drivers in Bleeding Disorder Testing Market Drivers Market Impact Demand for Confirmatory Testing of Acquired Hemophilia A Spontaneous bleeding without a prior bleeding history prompts factor VIII activity and inhibitor testing to confirm acquired hemophilia A and distinguish it from other coagulation disorders. Need for Factor-Specific Diagnosis in Rare Coagulation Deficiencies Overlapping symptoms across rare factor deficiencies increase the need for individual factor activity assays when routine coagulation tests cannot establish the cause. Demand for Functional Assessment of von Willebrand Factor Impaired von Willebrand factor function despite adequate levels increases the need for specialized activity assays to classify different forms of von Willebrand disease. Need for Laboratory Investigation of Unexplained Mucocutaneous Bleeding Recurrent nosebleeds, gum bleeding, and excessive menstrual bleeding support the use of specialized platelet function tests to identify suspected inherited platelet disorders. Demand for Coagulation Testing Before High-Risk Procedures in Patients with Suspected Bleeding Disorders A personal or family history of excessive bleeding can prompt targeted coagulation and platelet function tests before invasive procedures to assess potential bleeding risks.
01 Preanalytical Errors in Blood Sample Handling Increase Diagnostic Costs Blood samples used for bleeding disorder tests require accurate collection, correct citrate ratios, and timely processing to maintain sample integrity. Improper handling alters coagulation test results and leads to repeat sampling or additional laboratory investigations. Diagnostic laboratories face higher testing costs and reduced workflow efficiency.
02 Variability in Lupus Anticoagulant Testing Reduces Result Consistency Lupus anticoagulant testing relies on multiple coagulation assays whose results can vary according to reagent sensitivity, testing methods, and laboratory protocols. These differences complicate result interpretation and reduce consistency across diagnostic facilities. Laboratories face additional validation requirements and greater challenges when comparing results between testing centers.
July 2026 The U.S. FDA updated its approval information for WILATE, a von Willebrand factor and coagulation factor VIII concentrate, with an approval letter dated July 2, 2026.
June 2026 The U.S. FDA’s classification of von Willebrand factor assays under Class II medical devices with special controls took effect.